MCOV-B Medicover AB (publ)
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company operates through two segments: Healthcare Services and Diagnostic Services. Its Healthcare Services include outpatient and inpatient care; dental care, mental health care, orthopedics, preventive plans and sports, and wellness; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness; hospital care; and preventive care services. The company's Diagnostic Services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. It serves corporate, individuals, and public sector clients. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Medicover (STO: MCOV-B)
›
Medicover (STO: MCOV-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 49,000 employees.
The shares were at 259.00 SEK on 19 November 2026, up 6.9% over 52 weeks. Its 52-week range is 179.40 SEK to 284.50 SEK: the price is 9.0% below the high and 44.4% above the low.
At a market capitalisation of 39.36B SEK, it trades at 38.7 times trailing earnings. The median trailing P/E of its 18 largest Medical Care Facilities peers is 22.0, a premium of 75% for MCOV-B. It pays a dividend yielding 0.84% (it pays out 34% of its earnings), against a median of 0.66% among the dividend payers in that peer group.
Medicover reports return on equity of 14.5%, an operating margin of 7.4% and revenue up 6.0% year over year.
Its debt exceeds its cash by 1.18B EUR, a debt-to-equity ratio of 2.70. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 286.91 SEK is 10.8% above the current price. The next earnings report is expected on 10 February 2027.